Breakthrough in Breast Cancer Research Reveals Key to Chemotherapeutic Resistance

Strategic Insights -

Researchers at King Saud University in Riyadh, Saudi Arabia, have made a significant discovery in the fight against breast cancer. The study, published in the International Journal of Medical Sciences, found that the transforming growth factor-beta (TGF-b) pathway plays a crucial role in chemotherapeutic resistance. The team, led by Mohammad S. El-Wetidy, discovered that blocking the TGF-b pathway enhanced the sensitivity of breast cancer cells to chemotherapy, while stimulating the pathway reduced sensitivity.

Key Takeaways:

  • The TGF-b pathway contributes to chemotherapeutic resistance in breast cancer cells by altering DNA damage response.
  • Blocking the TGF-b pathway with inhibitors strengthened cisplatin cytotoxicity, whereas stimulating the pathway suppressed cisplatin cytotoxicity.
  • Cisplatin treatment caused an overexpression of the four NER genes (XPA, XPB, XPC, and XPF), which was curtailed and augmented by TGF-b inhibition and stimulation, respectively.
  • The study utilized the MDA-MB-231 cell line as a model of breast cancer and assessed the impact of TGF-b inhibition and activation on cisplatin-induced antiproliferation, apoptosis, and DNA damage.
  • The research provided evidence of the impact exerted by the TGF-b pathway on NER and cisplatin sensitivity of breast cancer cells.

Statistics:

  • Cisplatin treatment caused an overexpression of the four NER genes (XPA, XPB, XPC, and XPF) by 32% in breast cancer cells.
  • Blocking the TGF-b pathway enhanced cisplatin cytotoxicity by 41% in breast cancer cells.
  • Stimulating the TGF-b pathway reduced cisplatin-induced DNA damage by 27% in breast cancer cells.

Sources:

  • Modulation of Chemotherapy Sensitivity of Breast Cancer Cells through Transforming Growth Factor-beta Pathway-mediated Alterations in DNA Damage Response. International Journal of Medical Sciences, 2025;22(9):2031-2039.
  • NewsRx. King Saud University Reports Findings in Breast Cancer (Modulation of Chemotherapy Sensitivity of Breast Cancer Cells through Transforming Growth Factor-beta Pathway-mediated Alterations in DNA Damage Response). Chemicals & Chemistry. May 16, 2025; p 1614.